AREVA Med’s new clinical trial website, www.TargetedTrials.com, provides a comprehensive source of information for patients and physicians searching for innovative oncology trials.
Visitors will find information that describes the therapy, abdominal cancers, the clinical trial process and eligibility criteria for the Phase I trial underway at the University of Alabama at Birmingham (UAB). The clinical trial, the first to use lead-212 (212Pb), aims to evaluate a new approach for hard-to-treat cancers such as ovarian, pancreatic, colon, gastric, endometrial, and breast cancer that have spread to the abdominal cavity. With few options available for combating these cancers, AREVA Med hopes that this innovative radioimmunotherapy approach will eventually provide significant benefits to patients with abdominal metastatic cancers.
AREVA Med’s therapy, called ²¹²Pb-TCMC-Trastuzumab, uses a radioisotope attached to a monoclonal antibody. Radioimmunotherapy is a novel approach that destroys cancer cells by combining the accuracy and selectiveness of a monoclonal antibody with a powerful radioisotope. Simply put, the antibody transports and delivers the lead-212 (²¹²Pb) to the cancer cell. Lead-212 is a radioactive isotope with short-range energy that then kills the cancer cell.
This video shows AREVA Med’s radioimmunotherapy in action.
